On This Page:

The MODUS Study is a randomized feasibility study evaluating the safety and performance of hepatic (liver) denervation, renal (kidney) denervation or multi-organ (liver and kidney) denervation with Metavention’s iRF Denervation System for the treatment of type 2 diabetes and high blood pressure. Participants will receive one of these denervation treatments but will not know which one. This study is currently enrolling patients in Australia.

Who can be involved?

You may be eligible to participate if:

  • Aged between 22 and 70 years old
  • Type 2 diabetes diagnosis:

HbA1c between 48 mmol/mol (6.5%) and 69 mmol/mol(8.5%) AND on a consistent drug regimen up to 2 diabetes medications for at least 90 days
Diagnosis of high blood pressure AND on a consistent regimen of up to 2 antihypertensive medications for at least 90 days

  • Waist circumference Caucasians ≥ 102 cm (male) and ≥ 88 cm (female) or
  • Asians: ≥ 90 cm (male) and ≥ 80 cm (female)

For further information and to see if you are eligible please follow the below link: http://www.modusstudy-au.com/

This research project has been approved by The Alfred Human Research Ethics Committee: (HREC/60968/Alfred-2020).